Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc
(NQ:
VRCA
)
2.820
+0.030 (+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verrica Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
January 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
January 22, 2024
Giving the bears a rough time can yield massive gains for contrarians, thus drawing attention to these potential short-squeeze stocks.
Via
InvestorPlace
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
January 05, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
January 04, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Analysts Have This to Say About Verrica Pharmaceuticals
October 12, 2023
Via
Benzinga
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
January 03, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Top 4 Health Care Stocks That May Crash This Month
December 20, 2023
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Insiders Buying Pfizer And 3 Other Stocks
December 20, 2023
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.
Via
Benzinga
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
December 15, 2023
With Verrica Pharmaceuticals releasing positive Phase 3 trial results for a skin disease therapeutic, VRCA stock skyrocketed in response.
Via
InvestorPlace
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) Near the Top of Equities by Percentage Gain on 12/15
December 15, 2023
Via
Investor Brand Network
Analyst Ratings for Verrica Pharmaceuticals
August 10, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Verrica Pharmaceuticals: Here's What You Need To Know
July 27, 2023
Via
Benzinga
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 15, 2023
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 15, 2023
Via
Benzinga
Why Is Skin Disease-Focused Verrica Pharmaceuticals Stock Trading Higher Today?
December 15, 2023
Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, reported topline results from its Phase 3 trial of TO-208 (referred to as VP-102 and...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 15, 2023
Via
Benzinga
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
December 15, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
November 10, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For November 9, 2023
November 09, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via
Benzinga
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
October 25, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
September 27, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
August 24, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
August 23, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
August 10, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
August 03, 2023
Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
July 26, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval
July 25, 2023
Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.